Department of Respirology, Graduate School of Medicine, Chiba University, Japan.
Department of Cardiology, Kameda Medical Center, Japan.
Intern Med. 2023 Jan 15;62(2):275-279. doi: 10.2169/internalmedicine.9811-22. Epub 2022 Jun 14.
We herein report a case of pulmonary veno-occlusive disease (PVOD) induced by allo-hematopoietic stem cell transplantation (HSCT) in a 48-year-old man who was diagnosed with acute myeloid leukemia. Five months after transplantation, he developed dyspnea and was diagnosed with pulmonary hypertension based on right heart catheterization. Although he received treatment with pulmonary vasodilators, diuretics, and corticosteroids, his pulmonary artery pressure did not decrease, and his pulmonary edema worsened. Based on the clinical course, hypoxemia, diffusion impairment, and computed tomography findings, the patient was diagnosed with HSCT-related PVOD. Critical attention should be paid to dyspnea after HSCT for the early diagnosis of PVOD.
我们在此报告一例由异基因造血干细胞移植(HSCT)引起的肺静脉闭塞性疾病(PVOD)病例,该患者为 48 岁男性,诊断为急性髓系白血病。移植后 5 个月,他出现呼吸困难,并根据右心导管检查诊断为肺动脉高压。尽管他接受了肺动脉扩张剂、利尿剂和皮质类固醇治疗,但他的肺动脉压并未降低,肺水肿加重。根据临床过程、低氧血症、弥散障碍和计算机断层扫描结果,该患者被诊断为 HSCT 相关的 PVOD。对于 HSCT 后呼吸困难应给予密切关注,以便早期诊断 PVOD。